ZGN$11.55
$11.9
Chart
Performance
Key Stats
AI ZGN Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuyZegna exhibits a strong thematic alignment with the luxury goods market and demonstrates robust profitability. While current technical indicators suggest a neutral to slightly bearish short-term outlook, the company's solid fundamentals and dividend payouts make it an attractive long-term investment.
Thematic
Zegna is well-positioned within the resilient and growing global luxury market, benefiting from strong brand recognition and expansion strategies.
Fundamental
Zegna demonstrates solid revenue growth and profitability, supported by a manageable debt level and a healthy balance sheet. Its dividend yield adds to its fundamental appeal for income-focused investors.
Technical
The stock is trading near its 52-week high but shows mixed signals across various technical indicators, suggesting a period of consolidation or potential for a short-term reversal.
| Factor | Score |
|---|---|
| Luxury Goods Market Growth | 90 |
| Brand Strength & Recognition | 88 |
| Digital Transformation & E-commerce | 85 |
| Sustainability & ESG | 75 |
| Geographic Diversification | 80 |
| Factor | Score |
|---|---|
| Revenue Growth | 80 |
| Profitability | 65 |
| Valuation | 70 |
| Balance Sheet Health | 70 |
| Cash Flow | 85 |
| Dividends | 75 |
| Factor | Score |
|---|---|
| Trend | 70 |
| Momentum | 60 |
| Moving Averages | 65 |
| Volume | 70 |
| Short-term Oscillators | 40 |
AI Investing Checklist
Powered by LiveAIBullish Points (6)
Revenue Growth and Profitability
The company has shown revenue growth, with total revenue for 2024Q4 at $1,946,647,000. Net income for the same period was $77,083,000, with a net margin of 4.0%.
Strong Financial Position
Total equity stands at $982,887,000, with current assets of $1,206,162,000 and current liabilities of $852,885,000, indicating a healthy current ratio. Cash equivalents were $219,130,000 as of 2024Q4.
Bearish Points (6)
Declining Net Margin
The net margin has decreased from 6.4% in 2023Q4 to 4.0% in 2024Q4, indicating potential pressure on profitability.
Debt Levels
Total debt was $1,035,252,000 in 2024Q4, with non-current liabilities at $998,201,000, which might pose a risk if earnings decline.
Calendar
July 2025
7
Ex-Dividend Date
July 2025
29
Next Dividend Date
September 2025
5
Next Earnings Date
H: $
A: $
L: $
Profile
Ermenegildo Zegna N.V., together with its subsidiaries, designs, manufactures, markets, and distributes luxury menswear and womenwear, children's clothing, footwear, leather goods, and other accessories worldwide. The company offers luxury leisurewear, such as knitwear, jeans, jersey and shirts, fabric and leather outerwear, and accessories; formalwear, including formal suits to tuxedos, shirts, blazers, formal coats, and accessories; and leather accessories comprising sneakers and other shoes, bags, belts and small leather accessories. It also manufacturing and distribution of eyewear, cufflinks and jewelry, beachwear, underwear, and fragrances. In addition, the company offers fine jewelry, childrenswear, textile, and home design products. It sells its products under the ZEGNA, Thom Browne, and TOM FORD FASHION brands. The company serves its products through retail stores and online channels. The company was founded in 1910 and is based in Trivero, Italy. Ermenegildo Zegna N.V. operates as a subsidiary of Monterubello Societa' Semplice.
Seasonals
Price Target
8.86 USD
The 39 analysts offering 1 year price forecasts for ZGN have a max estimate of 10.72 and a min estimate of 7.45.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 98
Major medical device company with extensive neuromodulation and spine product portfolios, directly overlapping with Zynex's neuro-related and rehabilitation focus.
Weight: 97
Diversified healthcare company with a significant presence in neuromodulation devices, largely through its acquisition of St. Jude Medical.
Weight: 96
Key player in the neuromodulation market, offering devices for pain management and neurological conditions.
Weight: 95
Direct competitor specializing in neuromodulation devices, particularly for neurological disorders like depression, aligning with Zynex's neuro-diagnostics focus.